Latest news with #RichardPaolone
Yahoo
a day ago
- Business
- Yahoo
FluroTech Ltd. Announces Change in Directors
Calgary, Alberta--(Newsfile Corp. - June 13, 2025) - FluroTech Ltd. (TSXV: TEST.H) ("FluroTech" or the "Company") is pleased to announce that effective June 12, 2025, Eric Corbett has been appointed to the board of directors. Mr. Corbett is the Managing Director of Oakridge Securities Inc. which operates as a capital markets and corporate finance advisory business, where he has been employed since December 2024. From August 2017 to September 2024, Mr. Corbett was part of the corporate client group at Canadian Imperial Bank of Commerce, one of Canada's largest financial institutions, where he oversaw the execution of high-profile transactions, including providing debt capital to private and public businesses to support M&A transactions, shareholder buyouts, working capital support and sponsor backed equity investments. Mr. Corbett has served as a board member of Entero Therapeutics, Inc. (NASDAQ: ENTO) since February 2025 and Mixed Martial Arts Group Limited (NYSE: MMA) since April 2025. Mr. Corbett holds a Bachelor of Commerce degree from McMaster University and is also a CFA charterholder. Mr. Corbett has successfully completed the FINRA Securities Industry Essentials Exam, the CSI Canadian Securities Course and the CSI Conduct & Practices Handbook. Mr. Corbett is well qualified to serve on the board due to his specialization in capital allocation and corporate finance. About FluroTech Ltd. FluroTech was incorporated under the Business Corporations Act (Alberta) on May 24, 2018. FluroTech is currently inactive with limited operations and the Common Shares of FluroTech are currently halted on the NEX. FluroTech has no commercial operations and no assets other than cash and is a reporting issuer in the provinces of Alberta and British Columbia. For further information contact: Richard Paolone, Chief Executive OfficerFluroTech Ltd.c/o Borden Ladner Gervais LLPCentennial Place, 520 3 Ave SW Suite 1900Calgary, AB T2P 0R3Attention: Richard Paolone, President & CEOE-mail: rpaolone@ 1 (416) 258-3059 Neither Exchange nor its Regulation Services Provider (as such term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release. To view the source version of this press release, please visit
Yahoo
13-05-2025
- Business
- Yahoo
FluroTech Ltd. Announces Change in Management and Directors
Calgary, Alberta--(Newsfile Corp. - May 13, 2025) - FluroTech Ltd. (TSXV: TEST.H) ("FluroTech" or the "Company") announces that effective December 16, 2024, Dr. Brendan Miles and Michael Rodyniuk have resigned from the board of directors of the Company, with Michael Rodyniuk also resigning as President and CEO of the Company. Further, effective December 28, 2024, Danny Dalla-Longa has resigned from the board of directors of the Company. The Company would like to thank each of Dr. Brendan Miles, Michael Rodyniuk and Danny Dalla-Longa for their valuable contributions to the Company and wish them every success in their future endeavors. As of the date of Mr. Dalla-Longa's resignation, the Company's board is comprised of James O'Brien and Richard Paolone. We note that the Company is not currently in compliance with TSX Exchange (the "Exchange") Policy 3.1 regarding the minimum number of directors & independence requirements. The Company is actively searching for a replacement independent director for the Company's board with the intent of filling the vacant position by the end of June, 2025. The Company is also pleased to announce that, effective December 16, 2024, Richard Paolone has been appointed to the position of President and CEO of the Company. Mr. Richard Paolone is a practicing securities lawyer focused on mining, agriculture and cannabis. Mr. Paolone is the principal lawyer of Paolone Law Professional Corporation. In his private practice, he has developed experience with respect to public companies, capital markets, mergers and acquisitions and other facets fundamental to the natural resources sector. Mr. Paolone currently serves as Director and CEO of several other private and reporting companies. About FluroTech Ltd. FluroTech was incorporated under the Business Corporations Act (Alberta) on May 24, 2018. FluroTech is currently inactive with limited operations and the Common Shares of FluroTech are currently halted on the NEX. FluroTech has no commercial operations and no assets other than cash and is a reporting issuer in the provinces of Alberta and British Columbia. For further information contact: Richard Paolone, Chief Executive Officer FluroTech Ltd. c/o Borden Ladner Gervais LLP Centennial Place, 520 3 Ave SW Suite 1900 Calgary, AB T2P 0R3 Attention: Richard Paolone, President & CEO E-mail: rpaolone@ 1 (416) 258-3059 Neither Exchange nor its Regulation Services Provider (as such term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release. To view the source version of this press release, please visit
Yahoo
14-02-2025
- Business
- Yahoo
Entero Therapeutics Appoints Richard Paolone as CEO
BOCA RATON, Fla., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc. (Nasdaq: ENTO) ('Entero' or the 'Company'), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that the board of directors has appointed Mr. Richard Paolone as the interim CEO of the Company. Richard Paolone is a Toronto-based securities lawyer with extensive experience in corporate finance, securities law, and mergers and acquisitions. Mr. Paolone plays a key role in advising on a range of strategic business initiatives and has represented numerous companies in both private and public offerings of debt and equity securities, comprehensive understanding of capital markets and regulatory environments. His advisory work has been pivotal to several successful M&A and go-public transactions. In addition to his transactional work, Mr. Paolone has built a reputation as a trusted advisor to management teams and boards, ensuring legal and regulatory compliance in Canada while facilitating business growth. His broad experience also includes serving as a director or officer for several private and publicly traded companies, where he continues to provide strategic insights and governance expertise to help guide their success in competitive markets. For more information about Entero Therapeutics, visit and connect on X and LinkedIn. About Entero Therapeutics Entero Therapeutics, Inc., is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company's programs address significant unmet needs in GI health and include: latiglutenase, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency. For more information visit For more information:Entero Therapeutics, Inc.777 Yamato Road, Suite 502Boca Raton, FL 33431Phone: (561) 589-7020info@ Investor contact information:Entero Investor Relationsinvestors@ in to access your portfolio
